Question | Summary response |
---|---|
Q1: Knowledge of the Polypill concept | Â |
It has been hypothesized through a meta-analysis that a daily intake of a so-called Polypill (fixed combination of low dose ACE-I, statin, diuretic and aspirin) for life long may reduce the risk of CVD by more than 80%. These results, according to the hypothesis, are applicable to primary and secondary prevention. In a scale from 1 to 10 where 1 is the least and 10 is the maximum, how do you rate your knowledge about the Polypill? | Mean (SD); Median (Minimum, Maximum) 5.6 (2.2); 6.0 (1.0, 10.0) |
Q2: Agreement with Wald & Law on lack of need to routinely monitor CVD risk factors | Â |
The polypill strategy, as suggested by the authors, does not require routine monitoring or measuring the cardiovascular risk factors (such as blood pressure or cholesterol) in patients receiving the Polypill. This has been rationalized by the notion that CVD risk reduction by the Polypill is independent from the baseline value. In a scale from 1 to 10 where 1 is the least and 10 is the maximum, how do you rate your agreement on not to monitor the CVD risk factors in patients receiving the Polypill? | Mean (SD); Median (Minimum, Maximum) 2.9 (2.4); 2.0(1.0, 10.0) |
Q3: Most important factor for prescribing a Polypill | Â |
What would be the most important factor that determine your decision to prescribe the Polypill: | Â |
 | N (%) |
   Few side effects | 11(19.3) |
   Degree of CVD risk reduction | 28 (49.1) |
   Low cost | 5 (8.7) |
   Others | 14 (24.6) |
Q4: Acceptability to prescribe the Polypill for PRIMARY CVD prevention | Â |
If it is documented in a large clinical trial that a daily intake of the Polypill reduces the risk of major CVD in people without established CVD (primary prevention ), will you prescribe it to your patients? | Â |
 | N (%) |
   Yes, definitely | 39(67.2) |
   Yes, probably | 11(19.0) |
   No | 8 (13.8) |
Q5: Acceptability to prescribe the Polypill for SECONDARY CVD prevention | Â |
If it is documented in a large clinical trial that a daily intake of the Polypill reduces the risk of recurrent cardiovascular event in people with established CVD (secondary prevention) will you prescribe it to your patients? | Â |
 | N, (%) |
   Yes, definitely | 50 (86.2) |
   Yes, probably | 4 (6.9) |
   No | 4(6.9) |